&lt;Praxis Biologics Inc> said it
filed a registration statement with the Securities and Exchange
Commission for the initial public offering of 1.5 mln shares of
common.
    It said the offering is being managed by Shearson Lehman
Brothers Inc and Merrill Lynch Capital Markets.
    Praxis said it will use the proceeds to fund product
research and development costs and initially will focus on
vaccines for infants and young children.
 Reuter
&#3;